 Tenofovir
"Tenofovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
| Descriptor ID |
D000068698
|
| MeSH Number(s) |
D02.705.429.906 D03.633.100.759.138.881
|
| Concept/Terms |
Tenofovir- Tenofovir
- 9-(2-Phosphonylmethoxypropyl)adenine
- 9-PMPA (tenofovir)
- 9-(2-Phosphonomethoxypropyl)adenine
|
Below are MeSH descriptors whose meaning is more general than "Tenofovir".
Below are MeSH descriptors whose meaning is more specific than "Tenofovir".
This graph shows the total number of publications written about "Tenofovir" by people in this website by year, and whether "Tenofovir" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 2 | 2 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 5 | 5 | | 2014 | 1 | 5 | 6 | | 2015 | 4 | 2 | 6 | | 2016 | 12 | 3 | 15 | | 2017 | 7 | 3 | 10 | | 2018 | 10 | 1 | 11 | | 2019 | 5 | 4 | 9 | | 2020 | 4 | 10 | 14 | | 2021 | 1 | 12 | 13 | | 2022 | 0 | 12 | 12 | | 2023 | 0 | 12 | 12 | | 2024 | 8 | 2 | 10 | | 2025 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Tenofovir" by people in Profiles.
-
Mainella VA, Branchford B, Nemkov T, Hosford S, Coyle RP, Johnson B, Choi YJ, Williams M, Zheng JH, Bushman L, Kiser JJ, Anderson PL, Brooks KM. Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. J Antimicrob Chemother. 2025 May 02; 80(5):1224-1232.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. J Int AIDS Soc. 2025 Apr; 28(4):e26445.
-
McGarrity MW, MacPherson P, Li A, Naccarato M, Anderson P, Tan DHS. Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery. HIV Med. 2025 Apr; 26(4):643-649.
-
Gichane MW, Velloza J, Hosek S, Beauchamp G, Anderson P, Delany-Moretlwe S, Celum C. Hoping to Adhere? Examining the Relationship Between Hope and Pre-exposure Prophylaxis Willingness, Adherence, and Persistence Among Young Women in South Africa and Zimbabwe (HPTN 082). AIDS Behav. 2025 Feb; 29(2):527-534.
-
Ryan P, Odegard E, Meeds H, Lartey M, Ganu VJ, Tachi K, Yang H, Ojewale O, Boamah I, Obo-Akwa A, Antwi K, Anderson PL, Blackard JT, Kwara A. Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV/HIV coinfection. J Clin Virol. 2024 Dec; 175:105733.
-
Zhang HL, Mock M, Bushman L, Anderson PL, Kiser JJ, Naggie S. Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression. Clin Infect Dis. 2024 09 26; 79(3):705-708.
-
Joseph Davey D, Dadan S, Bheemraj K, Waitt C, Khoo S, Myer L, Wiesner L, Else L, Thompson B, Castel S, Wara N, Anderson PL, Orrell C. Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study. Antiviral Res. 2024 Nov; 231:106014.
-
Riddler SA, Kelly CW, Hoesley CJ, Ho KS, Piper JM, Edick S, Heard F, Doncel GF, Johnson S, Anderson PL, Brand RM, Kunjara Na Ayudhya RP, Bauermeister JA, Hillier SL, Hendrix CW. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. J Infect Dis. 2024 Sep 23; 230(3):696-705.
-
Wu L, Kinuthia J, Anderson PL, Baeten JM, Dettinger JC, Gandhi M, Gomez L, John-Stewart G, Marwa MM, Ngumbau N, Otieno F, Omondi P, Odhiambo B, Watoyi S, Pintye J. Drug Concentrations in Hair and Dried Blood Spots as Preexposure Prophylaxis Adherence Metrics During Pregnancy and Postpartum. J Infect Dis. 2024 Sep 23; 230(3):689-695.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|